Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
13.72
Nov 19 • 3:59 PM ET Dollar change+0.21 Percentage change(1.55%)
Aftermarket Close
14.00
Aftermarket • 5:26 PM ET Dollar change+0.28 Percentage change(2.04%)
Index
RUT
Market Cap
1.96B
Enterprise Value
1.66B
Income
-60.76M
Sales
0.00M
Book/sh
2.12
Cash/sh
2.10
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
34
IPO
May 07, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
6.46
P/C
6.53
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
38.86
Current Ratio
38.86
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.40
EPS next Y
-0.66
EPS next Q
-0.15
EPS this Y
-53.12%
EPS next Y
-34.52%
EPS next 5Y
-
EPS past 3/5Y
11.11% 29.44%
Sales past 3/5Y
- -
EPS Y/Y TTM
-6.57%
Sales Y/Y TTM
-
EPS Q/Q
-65.19%
Sales Q/Q
-
Insider Own
27.67%
Insider Trans
-0.10%
Inst Own
83.41%
Inst Trans
6.84%
ROA
-23.82%
ROE
-24.67%
ROIC
-20.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
0.03%
SMA50
-0.43%
SMA200
-5.84%
Trades
Shs Outstand
142.53M
Shs Float
103.11M
52W High
20.22 -32.15%
52W Low
9.82 39.71%
Volatility
6.72% 6.16%
ATR (14)
0.86
RSI (14)
49.70
Beta
1.14
Rel Volume
1.16
Avg Volume
1.97M
Volume
2,284,888
Perf Week
0.73%
Perf Month
7.44%
Perf Quarter
-23.61%
Perf Half Y
-3.11%
Perf YTD
9.58%
Perf Year
24.28%
Perf 3Y
887.05%
Perf 5Y
1194.34%
Perf 10Y
-
Prev Close
13.51
Price
13.72
Change %
1.55%
Consensus
Strong Buy
Avg. Price Target
$29.50
Implied Upside
+115.0%
Analysts11incl. previous ratings
Rating Distribution11 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 21, 2026Initiated
BMO logoBBMO Capital Markets
Outperform$36+162.4%
Nov 13, 2025Initiated
LLeerink Partners
Outperform$13-5.2%
Aug 21, 2025Initiated
MS logoMMorgan Stanley
Overweight$18+31.2%
Jul 01, 2025Initiated
CCantor Fitzgerald
Overweight$25+82.2%
May 28, 2025Initiated
HH.C. Wainwright
Buy$21+53.1%
Mar 10, 2025Upgrade
RJF logoRRaymond James
Outperform → Strong Buy$9 → $29+111.4%
Mar 10, 2025Reiterated
NNeedham
Buy$8 → $25+82.2%
Dec 12, 2024Reiterated
HH.C. Wainwright
Buy$6 → $7.50-45.3%
Sep 09, 2024Resumed
LLeerink Partners
Outperform$6 → $7-49.0%
Aug 30, 2024Initiated
RJF logoRRaymond James
Outperform$9-34.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heffernan Michael ThomasDirectorSep 15 '26Option Exercise3.1939,473126,10327,403Sep 17 04:55 PM
Heffernan Michael ThomasDirectorSep 15 '26Sale15.0939,473595,8066,351Sep 17 04:55 PM
MICHAEL HEFFERNANDirectorSep 15 '26Proposed Sale15.8939,473627,226Sep 15 04:42 PM
Galletta ChristopherSee RemarksDec 02 '25Option Exercise0.514,2252,15926,095Dec 03 04:16 PM
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
Co-FounderMs. Jennifer L. Good
Chief Development OfficerDr. James V. Cassella Ph.D.
Chief Commercial OfficerDr. Farrell Simon Pharm.D.
Co-Founder & Chief Scientific OfficerDr. Thomas R. Sciascia M.D.
Chief Financial Officer & Principal Financial OfficerMr. David C. Hastings CPA